These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 27718039)
1. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines. Lompardía SL; Díaz M; Papademetrio DL; Pibuel M; Álvarez É; Hajos SE Invest New Drugs; 2017 Feb; 35(1):1-10. PubMed ID: 27718039 [TBL] [Abstract][Full Text] [Related]
2. Hyaluronan abrogates imatinib-induced senescence in chronic myeloid leukemia cell lines. Lompardía S; Díaz M; Pibuel M; Papademetrio D; Poodts D; Mihalez C; Álvarez É; Hajos S Sci Rep; 2019 Jul; 9(1):10930. PubMed ID: 31358779 [TBL] [Abstract][Full Text] [Related]
3. Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib. Lompardía SL; Díaz M; Papademetrio DL; Mascaró M; Pibuel M; Álvarez E; Hajos SE Glycobiology; 2016 Apr; 26(4):343-52. PubMed ID: 26582603 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095 [TBL] [Abstract][Full Text] [Related]
5. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib. Yandim MK; Ceylan C; Elmas E; Baran Y Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223 [TBL] [Abstract][Full Text] [Related]
7. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells. Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514 [TBL] [Abstract][Full Text] [Related]
8. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353 [TBL] [Abstract][Full Text] [Related]
9. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells. Li X; Pang J; Xue W; Wang Y; Tian T; Elgehama A; Wu X; Wu X; Sun Y; Qiu H; Shen Y; Xu Q Toxicol Appl Pharmacol; 2018 Dec; 360():249-256. PubMed ID: 30290167 [TBL] [Abstract][Full Text] [Related]
10. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia]. Tsubaki M Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658 [TBL] [Abstract][Full Text] [Related]
11. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells. Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938 [TBL] [Abstract][Full Text] [Related]
12. Human leukemic cell lines synthesize hyaluronan to avoid senescence and resist chemotherapy. Lompardía SL; Papademetrio DL; Mascaró M; Álvarez EM; Hajos SE Glycobiology; 2013 Dec; 23(12):1463-76. PubMed ID: 24013961 [TBL] [Abstract][Full Text] [Related]
13. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515 [TBL] [Abstract][Full Text] [Related]
14. Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells. Liu Z; Zheng W; Liu Y; Zhou B; Zhang Y; Wang F Exp Cell Res; 2021 Aug; 405(2):112708. PubMed ID: 34157313 [TBL] [Abstract][Full Text] [Related]
15. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression. Tan Z; Peng A; Xu J; Ouyang M BMC Anesthesiol; 2017 Sep; 17(1):132. PubMed ID: 28962554 [TBL] [Abstract][Full Text] [Related]
16. Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells. Yin Y; Sun H; Xu J; Xiao F; Wang H; Yang Y; Ren H; Wu CT; Gao C; Wang L Leuk Lymphoma; 2015 Jun; 56(6):1813-20. PubMed ID: 25146433 [TBL] [Abstract][Full Text] [Related]
17. Local Anesthetic Drug Inhibits Growth and Survival in Chronic Myeloid Leukemia Through Suppressing PI3K/Akt/mTOR. Zheng Q; Peng X; Yu H Am J Med Sci; 2018 Mar; 355(3):266-273. PubMed ID: 29549929 [TBL] [Abstract][Full Text] [Related]
18. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells. He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093 [TBL] [Abstract][Full Text] [Related]
19. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells. Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793 [TBL] [Abstract][Full Text] [Related]
20. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation. Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]